
Evrys Bio LLC (AKA: Forge Life Sciences LLC) Profile last edited on: 12/14/2023
CAGE: 5UBY1
UEI: TM98GAF3Z6Q6
Business Identifier: Novel broad-spectrum anti-viral therapies: first-in-class antivirals safe - addressing problem of acquired drug-resistance, and providing unique broad-spectrum treatment options Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
3805 Old Easton Road
Doylestown, PA 18902
Doylestown, PA 18902
(267) 893-6755 |
business@evrysbio.com |
www.forgelifescience.com |
Location: Single
Congr. District: 01
County: Bucks
Congr. District: 01
County: Bucks
Public Profile
Evrys Bio - formerly dba Forge Life Sciences LLC - is a pre-clincial biotechnology company developing anti-viral treatments. Anchored in technology licensed from Princeton University, Evrys Bio is developing anti-viral therapies based on sirtuin modulators. Traditional antivirals are direct-acting antivirals targeting a protein of a specific virus limiting their effectiveness against more than one virus type. Where immuno-oncology drugs engage the patients immune system to fight cancer, Evrys Bio antivirals engage the cells intrinsic immunity to defend against infection. The vision is to develop first-in-class antivirals that are safe, address the problem of acquired drug-resistance, and provide unique broad-spectrum treatment options. If successful, the approach could potentially transform the practice of medicine - addressing the infectious disease condition as opposed to targeting a specific virus-type. The physician would be prescribing a safe, broad-spectrum antiviral, without the risk of acquired drug-resistance, based on symptom presentation, and prior to diagnostic confirmation of infecting virus-type.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
15-19Revenue Range
1.5M-2MVC funded?
YesPublic/Private
Privately HeldStock Info
----IP Holdings
10-14Awards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2023 | 2 | NIH | $5,126,080 | |
Project Title: A Single Antiviral to Treat Multiple Opportunistic Infections | ||||
2021 | 1 | NIH | $300,000 | |
Project Title: Development of a host-targeted antiviral as a chronic hepatitis B therapeutic with potential to achieve a functional cure | ||||
2019 | 2 | NIH | $2,304,858 | |
Project Title: Sirtuin Agonists as Pan Influenza Antivirals | ||||
2018 | 1 | CBD | $149,997 | |
Project Title: Host-Targeted Antiviral Drugs Providing Rapid, Scalable, Stable, Broad-Spectrum MedicalCountermeasure Against Marburg Virus | ||||
2015 | 1 | NIH | $224,999 | |
Project Title: An Antiviral to Treat Progressive Multifocal Leukoencephalopathy_(Pml) |
Key People / Management
Lillian W Chiang -- Founder, President and Chief Executive Officer
Justine Bucholz -- Chief of Operations and Project Management
F Aaron Dubberley -- Head of Intellectual Properties
Dana M Fowlkes -- Chief Business Officer
Emre Koyuncu -- Head of Biology
Eain A Murphy -- Head of Biology
Stacy W Remiszewski -- Head of Chemistry
Thomas E Shenk -- Founder and Board Director
Matthew Todd -- Head of Enzymology and Biophysics
James Tonra -- Chief Scientific Officer
Justine Bucholz -- Chief of Operations and Project Management
F Aaron Dubberley -- Head of Intellectual Properties
Dana M Fowlkes -- Chief Business Officer
Emre Koyuncu -- Head of Biology
Eain A Murphy -- Head of Biology
Stacy W Remiszewski -- Head of Chemistry
Thomas E Shenk -- Founder and Board Director
Matthew Todd -- Head of Enzymology and Biophysics
James Tonra -- Chief Scientific Officer